Authors: Braess, J Jahns-Streubel, G Voss, S Kern, W Keye, S Schleyer, E Hiddemann, W

Citation: J. Braess et al., The endogenous leukemic proliferation rate and cytosine arabinoside pharmacodynamics are major determinants for therapeutic success in acute myeloid leukemia, INT J CL PH, 38(3), 2000, pp. 150-151

Authors: Braess, J Voss, S Jahns-Streubel, G Schoch, C Haferlach, T Kern, W Keye, S Schleyer, E Hiddemann, W

Citation: J. Braess et al., The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with ahigh proliferative activity, BR J HAEM, 110(1), 2000, pp. 170-179

Authors: Braess, J Wegendt, C Jahns-Streubel, G Kern, W Keye, S Unterhalt, M Schleyer, E Hiddemann, W

Citation: J. Braess et al., Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine, BR J HAEM, 109(2), 2000, pp. 388-395